Castle Biosciences INC Form 4 insider transactions

Castle Biosciences' Chief Financial Officer, Frank Stokes, sold a total of 6,923 shares of common stock on November 15, 2024, under a pre-arranged 10b5-1 trading plan.

Castle Biosciences CEO Derek Maetzold executed multiple sales of company stock on November 12, 2024, under a pre-arranged 10b5-1 trading plan.

Tobin W. Juvenal, Chief Commercial Officer of Castle Biosciences, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Derek Maetzold, CEO of Castle Biosciences, executed multiple sales of common stock on November 4, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Tobin W. Juvenal, Chief Commercial Officer of Castle Biosciences, exercised stock options and sold shares of common stock on November 1, 2024, according to a Form 4 filing with the SEC.

Director Daniel Bradbury of Castle Biosciences sold shares of the company's common stock on November 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences CEO Derek Maetzold executed sales of common stock on October 14, 2024, through a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences' CEO, Derek Maetzold, executed multiple sales of common stock on October 8, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Daniel Bradbury of Castle Biosciences sold shares of common stock on October 7, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Derek Maetzold, CEO of Castle Biosciences, sold shares of common stock on October 4, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Derek Maetzold, CEO of Castle Biosciences, sold shares of common stock on September 16, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Derek Maetzold, CEO of Castle Biosciences, sold shares of common stock on September 11, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Derek Maetzold, CEO of Castle Biosciences, sold shares of common stock through a pre-arranged Rule 10b5-1 trading plan.

Director Daniel Bradbury of Castle Biosciences sold shares of common stock on September 5, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Derek Maetzold, CEO of Castle Biosciences, executed multiple sales of common stock on September 3rd and 4th, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Kristen Oelschlager, COO of Castle Biosciences, sold shares of common stock on September 3, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences CEO Derek Maetzold sold shares of the company's common stock on August 29 and 30, 2024, under a pre-arranged Rule 10b5-1 trading plan.

CEO Derek Maetzold of Castle Biosciences sold shares of common stock on August 23 and August 26, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Daniel Bradbury of Castle Biosciences sold shares of common stock on August 12, 2024, under a pre-arranged Rule 10b5-1 trading plan.

CEO of Castle Biosciences, Derek Maetzold, reports acquisition and disposal of company stock, including vesting of performance-based stock units and transactions within related trusts.

Tobin W. Juvenal, Chief Commercial Officer of Castle Biosciences, reports the vesting of performance-based stock units and a disposition of shares to cover tax obligations.

Kristen Oelschlager, COO of Castle Biosciences, reports acquisition and disposal of company stock and performance-based stock units.

Frank Stokes, CFO of Castle Biosciences, reports the vesting of performance-based stock units and a disposition of shares to cover tax obligations.

Frank Stokes, CFO of Castle Biosciences, sold a total of 10,000 shares of common stock on August 7, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Kristen Oelschlager, Chief Operating Officer of Castle Biosciences, sold shares of common stock on August 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Kristen Oelschlager, Chief Operating Officer of Castle Biosciences, sold 2,793 shares of common stock at a weighted-average price of $22.063 per share on July 29, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Daniel Bradbury, a director at Castle Biosciences, amended a previous SEC filing to include indirect holdings of common stock held in trusts and an LLC.

Director Kim Caple exercised stock options on July 14, 2024, acquiring 440 shares of Castle Biosciences common stock.

Director Ellen Goldberg exercised stock options, acquiring 440 shares of Castle Biosciences common stock on July 14, 2024.

Kristen Oelschlager, Chief Operating Officer of Castle Biosciences, sold 2,793 shares of common stock at a weighted-average price of $21.224 per share on July 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.